However, we suggest that PI3Kδ inhibitors might be of therapeutic relevance in areas where suppression of CD8+ T cells is useful, e.g. in transplantation medicine or in the treatment of autoimmune diseases and chronic obstructive pulmonary disease (COPD). This evidence concerns the gene CD8A and autoimmune disease.